@article{c3238ffe0c0f41e6b1a60ef85bf15560,
title = "Phase 1 Study of Tru-016, An Anti-CD37 SMIP{\texttrademark} Protein in Na{\"i}ve and Relapsed and/or Refractory CLL Patients",
author = "Awan, \{Farrukh T\} and Pagel, \{John M.\} and Andritsos, \{Leslie A\} and Gopal, \{Ajay K.\} and Furman, \{Richard R.\} and Stephen Spurgeon and Delva Deauna-Limayo and Scott Stromatt and Byrd, \{John C.\}",
note = "Abstract 1792 Background: CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of maturational stages. TRU-016 is a novel humanized anti-CD37 protein therapeutic that has demonstrated significantly greater direct killing of CLL cells than rituximab and greater Fc-mediated cellular cytotoxicity of CLL cells than either alemtuzumab or rituximab in pre-clinical models.",
year = "2011",
month = nov,
day = "18",
language = "American English",
volume = "118",
journal = "Blood",
}